Treatment of Systemic Sclerosis - Associated Interstitial Lung Disease: Evidence Based Recommendations 

The webinar you viewed presented the recently published clinical practice guideline on the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence Based Recommendations. 

The treatment recommendations and the evidence on which they are based will be discussed with attention paid to the risks and benefits associated with the different treatment options and considerations for shared-decision making. 

The webinar also featured insight into the guidelines from a pulmonologist and rheumatologist specializing in SSc-ILD.

Learning Objectives

 

  1. Describe the evidence behind treatments used for SSc-ILD 

  1. Describe and weigh the risks and benefits of treatments used for SSc-ILD 

  1. Incorporate patient preferences when determining the optimal treatment options for patients with SSc-ILD 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    The American Thoracic Society designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Participation
Publication Date: 
11/07/2023
Credit Expires: 
11/07/2024
Rating: 
0

ACCREDITATION STATEMENT

The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DISCLOSURE DECLARATIONS

It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. To see the most recent policies regarding potential conflicts of interest as well as the mechanisms to resolve such conflicts, press the COI Policy link below.

This educational activity may include discussion of unapproved uses of a drug, product, or device. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    The American Thoracic Society designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Participation
Please login or register to take this course.

 

To start this learning activity, press the Take Activity button. Then follow the on-screen instructions.

The system keeps track of your progress. If you close the activity and resume it later, it will re-start where you left off.